Under the normalization of drug sampling inspections, the quality of products of such enterprises still needs to be improved

In recent years, with the promulgation and implementation of a series of quality supervision bills by the regulatory authorities, various localities have imposed more targeted and strict supervision on drug quality and safety risks
.
In this context, localities have begun to conduct random inspections more and more frequently and have issued announcements
.
It is understood that on September 26, the Guangdong Provincial Food and Drug Administration issued a phase 2 drug random inspection information notice, and a total of 9 batches of drugs did not meet the drug standards
.
Specifically, in the sixth phase of Guangdong Province, a total of 1352 batches of 657 drugs from 79 drug manufacturers, 306 drug distributors and 93 medical institutions were sampled
.
Among them, 3 batches of 3 varieties did not meet the requirements of drug standards after inspection
.
In the seventh phase of Guangdong Province, 89 drug manufacturers, 402 drug distributors, and 150 medical institutions totaled 1,780 batches of 799 varieties of drugs, and 6 batches of 5 varieties did not meet the drug standards after inspection
.
It should be noted that most of the above varieties that do not meet the requirements of the drug standards are traditional Chinese medicine products, including tuckahoe bark, yam, and dandelion
.
Industry analysts believe that, on the whole, frequent random inspections actually mean that drug safety issues have become the focus of attention in the industry
.
In order to strengthen drug quality supervision and ensure the safety of drug use by the public, in fact, relevant departments have been making unremitting efforts to continuously strengthen drug quality supervision and random inspection
.
In the recent past, with the exception of Guangdong Province, many pharmaceutical companies have been announced and punished for producing and selling counterfeit and inferior drugs announced by the Drug Administration of each province
.
For example, on September 17, the Jiangxi Provincial Food and Drug Administration also issued the "Announcement on the fourth phase of drug supervision and sampling inspection information in 2021.

" A total of 22 batches of 20 varieties did not meet the requirements.
The non-compliant items included traits, moisture, weight differences, and content determination
.
On the whole, the unqualified medicines are mostly Chinese herbal medicines, decoction pieces and oral solid preparations
.
Among them, unqualified Chinese herbal medicines and decoction pieces still account for the majority
.
In this regard, the industry believes that in the context of increasingly strict supervision of the traditional Chinese medicine decoction piece industry, relevant pharmaceutical companies need to further strengthen self-discipline, and strictly follow the requirements of the new version of the pharmacopoeia, and do a good job in planting, production, processing, circulation and other links.
Work to boost the overall quality of the decoction pieces industry
.
In short, quality safety has become an important issue affecting the development of the pharmaceutical industry
.
In order to strengthen the supervision of drug quality and ensure the safety of drug use by the public, the country and even localities are constantly introducing relevant documents and measures to supervise the quality and safety of drugs
.
Affected by this, the industry believes that as a drug manufacturer, in addition to strictly complying with laws and regulations, control the production quality of all links; it also needs to continuously innovate and improve the system to enhance product competitiveness and continuously improve the management of drug safety risks.
Challenge the ability and level, and promote the high-quality development of the entire pharmaceutical industry
.